We are live on
!
Find out more
KCM
Kynam Capital Management Portfolio holdings
AUM
$1.62B
1-Year Est. Return
138.67%
This Fund
S&P 500
This Quarter
Est. Return
+55.71%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.57B
AUM Growth
+$222M
(+17%)
Cap. Flow
-$306M
Cap. Flow
% of AUM
-19.56%
Top 10 Holdings %
Top 10 Hldgs %
71.87%
Holding
41
New
6
Increased
4
Reduced
24
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CytomX Therapeutics
CTMX
|
+$20.2M |
| 2 |
KALV
KalVista Pharmaceuticals
KALV
|
+$16M |
| 3 |
Biohaven
BHVN
|
+$8.71M |
| 4 |
Cullinan Oncology
CGEM
|
+$7.32M |
| 5 |
Alector
ALEC
|
+$3.55M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viridian Therapeutics
VRDN
|
+$81.1M |
| 2 |
Cogent Biosciences
COGT
|
+$48.4M |
| 3 |
CG Oncology
CGON
|
+$43.8M |
| 4 |
enGene Therapeutics
ENGN
|
+$28.1M |
| 5 |
MBX
MBX Biosciences
MBX
|
+$25.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Biohaven
BHVN
$2.16B
| $7.94M | 0.51% |
+702,884
| New | +$8.71M |
|
27
Design Therapeutics
DSGN
$736M
| $7.36M | 0.47% |
784,606
-244,973
| -24% | -$1.92M |
|
28
Sutro Biopharma
STRO
$379M
| $5.55M | 0.35% |
479,590
-29,220
| -6% | -$277K |
|
|
AMRN
29
Amarin Corp
AMRN
$284M
| $5.43M | 0.35% |
389,273
-186,838
| -32% | -$3.08M |
|
30
Geron
GERN
$911M
| $4.56M | 0.29% |
3,456,318
| – | – |
|
|
CLYM
31
Climb Bio
CLYM
$735M
| $4.11M | 0.26% |
1,028,341
| – | – |
|
32
Caribou Biosciences
CRBU
$156M
| $3.98M | 0.25% |
2,503,302
-564,472
| -18% | -$1.18M |
|
33
PUT
Omeros
OMER
$709M
| $3.44M | 0.22% |
+200,000
| New | +$1.72M |
|
|
EVMN
34
Evommune Inc
EVMN
$409M
| $3.18M | 0.2% |
+185,482
| New | +$3.48M |
|
35
ProQR Therapeutics
PRQR
$243M
| $3.16M | 0.2% |
1,566,317
-83,145
| -5% | -$194K |
|
|
36
Alector
ALEC
$164M
| $3.12M | 0.2% |
+2,000,000
| New | +$3.55M |
|
37
Prelude Therapeutics
PRLD
$305M
| $2.29M | 0.15% |
+788,867
| New | +$1.33M |
|
38
Edgewise Therapeutics
EWTX
$4.39B
| – | – |
-253,979
| Closed | -$4.12M |
|
39
Ironwood Pharmaceuticals
IRWD
$611M
| – | – |
-5,466,825
| Closed | -$7.16M |
|
40
UroGen Pharma
URGN
$2B
| – | – |
-282,412
| Closed | -$6.94M |
|
41
United Therapeutics
UTHR
$26.3B
| – | – |
-67,588
| Closed | -$20M |
|
Similar funds
IPW
WIC
HH
TLFA
KCM
PRA
BW
CC
Kynam Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, Kynam Capital Management held 41 positions worth $1.57B, up 17% from $1.34B the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Kynam Capital Management withdrew a net $306M in Q4 2025, closing 4 positions and reducing 24 holdings. Its most notable exit was United Therapeutics, an estimated $20M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.
Against the trend, Kynam Capital Management opened a new position in Biohaven worth $7.94M.
- Kynam Capital Management's largest Q4 2025 buy was Biohaven: 702,884 shares worth $7.94M.
- Kynam Capital Management added most to CytomX Therapeutics in Q4 2025, an estimated $20.2M increase.
- Kynam Capital Management's biggest Q4 2025 reduction was Viridian Therapeutics, cutting an estimated $81.1M.
- Kynam Capital Management fully exited United Therapeutics in Q4 2025, selling an estimated $20M.
- Kynam Capital Management's ten largest holdings make up 72% of its $1.57B portfolio in Q4 2025.
- Kynam Capital Management opened 6 new positions and closed 4 in Q4 2025.
- Kynam Capital Management's portfolio value rose 17% quarter-over-quarter to $1.57B.
Based on Kynam Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.